British Journal of Haematology | 2019
Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma
Abstract
Arkenau, H.T., Olmos, D., Ang, J.E., De Bono, J., Judson, I. & Kaye, S. (2008) Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. British Journal of Cancer, 98, 1029–1033. Horstmann, E., Mccabe, M.S., Grochow, L., Yamamoto, S., Rubinstein, L., Budd, T., Shoemaker, D., Emanuel, E.J. & Grady, C. (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. New England Journal of Medicine, 352, 895–904. Kimmelman, J. (2017) Is participation in cancer phase I trials really therapeutic? Journal of Clinical Oncology, 35, 135–138. Peppercorn, J. (2006) Ethical issues in phase I cancer clinical trials. International Journal of Pharmaceutical Medicine, 20, 233–242. Weber, J.S., Levit, L.A., Adamson, P.C., Bruinooge, S.S., Burris, H.A. 3rd, Carducci, M.A., Dicker, A.P., Gonen, M., Keefe, S.M., Postow, M.A., Thompson, M.A., Waterhouse, D.M., Weiner, S.L. & Schuchter, L.M. (2017) Reaffirming and clarifying the American Society of Clinical Oncology’s Policy Statement on the Critical Role of Phase I trials in cancer research and treatment. Journal of Clinical Oncology, 35, 139–140. Wheler, J., Tsimberidou, A.M., Hong, D., Naing, A., Falchook, G., Piha-Paul, S., Fu, S., Moulder, S., Stephen, B., Wen, S. & Kurzrock, R. (2012) Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clinical Cancer Research, 18, 2922–2929.